The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases (Q37700289)

22 August 2017

1 reference

title

The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases (English)

1 reference

22 August 2017

Yasumichi Hitoshi

1

1 reference

22 August 2017

Nan Lin

series ordinal

2

1 reference

22 August 2017

Donald G Payan

series ordinal

3

1 reference

22 August 2017

Vadim Markovtsov

series ordinal

4

1 reference

22 August 2017

27 February 2010

1 reference

International Journal of Hematology

22 August 2017

1 reference

22 August 2017

91

1 reference

22 August 2017

2

1 reference

22 August 2017

189-200

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-010-0531-y

22 August 2017

0 references

cites work

The Janus kinases (Jaks)

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0531-Y

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12185-010-0531-Y

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

21 January 2018

1 reference

12 December 2020

Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.

1 reference

12 December 2020

Myeloproliferative disorders

1 reference

12 December 2020

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

12 December 2020

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

1 reference

12 December 2020

Modern management of myelofibrosis

1 reference

12 December 2020

Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses

1 reference

12 December 2020

Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis

1 reference

12 December 2020

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor

1 reference

12 December 2020

Tumour stem cells and drug resistance

1 reference

12 December 2020

Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity

1 reference

12 December 2020

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

12 December 2020

Clinical perspectives of concepts on neoplastic stem cells and stem cell-resistance in chronic myeloid leukemia.

1 reference

12 December 2020

Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers.

1 reference

12 December 2020

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

12 December 2020

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

12 December 2020

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

12 December 2020

Fragment-based discovery of JAK-2 inhibitors

1 reference

12 December 2020

Targeting cancer stem cells.

1 reference

12 December 2020

Drug Discovery and Development of Innovative Therapeutics--IBC's 13th Annual World Congress. Approaches to cancer therapy

1 reference

12 December 2020

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

12 December 2020

JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation model

1 reference

12 December 2020

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

1 reference

12 December 2020

Mechanisms of Disease: cancer stem cells--targeting the evil twin

1 reference

12 December 2020

Defective lymphoid development in mice lacking Jak3

1 reference

12 December 2020

Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction

1 reference

12 December 2020

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity

1 reference

12 December 2020

Defects in B lymphocyte maturation and T lymphocyte activation in mice lacking Jak3

1 reference

12 December 2020

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

12 December 2020

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

12 December 2020

Partial impairment of cytokine responses in Tyk2-deficient mice

1 reference

12 December 2020

The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

1 reference

12 December 2020

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

1 reference

12 December 2020

Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival

1 reference

12 December 2020

Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

12 December 2020

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

1 reference

12 December 2020

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

1 reference

12 December 2020

Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).

1 reference

12 December 2020

JAK-STAT signaling: from interferons to cytokines

1 reference

12 December 2020

Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains

1 reference

12 December 2020

10.1007/S12185-010-0531-Y

Identifiers

DOI

1 reference

22 August 2017

1 reference